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constituents through August 1, 2007, of which evidence from 27
were extracted using our criteria. Stakeholder comments on the
HTA process and decision methodology were distilled into 12
categories, ranging from impact of severity/rarity of disease on
acceptability of cost-effectiveness thresholds to over-reliance of
QALYs in decision-making. Compared to attributes reported for
other countries, NICE’s criteria and methods for health eco-
nomic assessment and decision-making varied substantially, such
as that of the model perspective, e.g., payer versus societal.
CONCLUSION: We found that aspects of NICE technology
appraisals garner criticism common to many stakeholders. This
underscores the need to reconsider how current health economic
and decision methodology might be improved. Furthermore,
country-level heterogeneity in HTA processes and methods sug-
gests the need to determine why these variations arise, and
whether they reﬂect societal preferences or misunderstandings of
appropriate methods.
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OBJECTIVE: Political objectives may alter economic rationale in
health care decision-making. The Hungarian government had
promised to reduce the prices and copayment of pharmaceuti-
cals, therefore 15% price cut was mandated to all reimbursed
pharmaceuticals from April 2004. Three months later the regu-
lation was abrogated by the Constitution Court. As the govern-
ment did not want to communicate a price increase, the level of
copayment remained the same, while the reimbursement level
was increased. It took two years to increase the copayment back
to the original level by a 7.5% reimbursement reduction in
February 2005, and by a further 7.5% reduction from February
2005 to July 2006. Our objective was to measure the impact of
price cut on the public pharmaceutical budget. METHODS: An
estimated public pharmaceutical spending was calculated based
upon projections from the expenditure in previous periods.
Only pharmaceuticals with reimbursement in April 2004 were
included into the analysis. The estimated expenditure was com-
pared to the real expenditure. Hungarian Forint was converted to
US$ by employing the quarterly exchange rate. RESULTS: In Q2
2004 the mandated price cut resulted in $39.65 million savings in
the pharmaceutical expenditure. In Q3-Q4 2004 the reduced
copayment generated $29.98 million increase in the drug budget.
Between Q1 2005 and Q2 2006 the impact of reduced copay-
ment was $42.42 million. CONCLUSION: The mandated price
cut and its subsequent abrogation resulted in $32.75 million
increase in the Hungarian public pharmaceutical expediture
between April 2004 and June 2006, as the government did not
dare to withdraw its promise on cheaper pharmaceuticals. Our
estimate is conservative, as the mandated price cut inﬂuenced
spending not only on pharmaceuticals with reimbursement in
April 2004, but via reference pricing also the spending on new
pharmaceuticals with initial reimbursement between April 2004
and June 2006.
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AMONG CHRONICALLY ILL ELDERLY POPULATION
Khan N1, Kaestner R2
1University of New Mexico, Albuquerque, NM, USA, 2University of
Illinois at Chicago, Chicago, IL, USA
OBJECTIVE: To estimate the effect of prescription drug insur-
ance on health, as measured by self-reported poor health status,
functional disability, and hospitalization among elderly with at
least three chronic conditions. METHODS: Analyses are based
on a nationally representative sample of non-institutionalized
elderly (>64 years of age) from the Medicare Current Beneﬁ-
ciary Survey (MCBS) for years 1992–2000. Estimates are
obtained using multivariable regression models that control for
observed characteristics and unmeasured person-speciﬁc effects
(i.e., ﬁxed effects). Fixed effects analysis uses within person
variation in drug coverage to estimate the effect of gaining or
losing coverage on outcome of interest (i.e., health). RESULTS:
In general, prescription drug insurance was not associated with
signiﬁcant changes in self-reported health, and hospitalization.
However, prescription drug coverage decreased functional dis-
ability slightly (4% improvement), although this was not sta-
tistically signiﬁcant. CONCLUSION: Findings suggest that
prescription drug coverage may have some health beneﬁts for
chronically ill.
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OBJECTIVE: During the 16 months preceding the start of the
Medicare prescription drug program (Part D), 22,359 vulnerable
Medicare beneﬁciaries with rheumatoid arthritis (RA) or mul-
tiple sclerosis (MS) participated in the Medicare Replacement
Drug Demonstration (MRDD), which provided access to spe-
cialty biologic medications. We examine beneﬁciary characteris-
tics associated with Part D enrollment among this population in
early 2006. METHODS: Predictors in multivariate logistic
regressions included female gender, age, race (white, black, or
other), region of the U.S., urban residence, Hierarchical Condi-
tion Category score (HCC; a measure of comorbidity), use of the
MRDD beneﬁt, subsidy level under the MRDD, self-report of
other drug coverage during the MRDD, and death within six
months of the start of Part D. RESULTS: Among 14,963 MRDD
beneﬁciaries with RA, 12,174 (81%) enrolled in Part D plans
during the ﬁrst half of 2006. Ninety percent (6646) of the 7396
beneﬁciaries with MS enrolled in a Part D plan—about 50%
higher than the rate of enrollment in the general Medicare popu-
lation. Female gender (OR = 1.5, 1.3–1.6), MRDD beneﬁt use
(OR = 2.6, 2.4–2.8), higher HCC score (OR = 1.07, 1.03–1.10),
other drug coverage during the MRDD (OR = 1.6, 1.5–1.7),
were associated with Part D enrollment. There were regional
differences as well. Older age (OR = 0.9, 0.9–0.9) and death
within 6 months (OR = 0.3, 0.3–0.4) were associated with not
enrolling in Part D. Separate regressions for the RA and MS
populations produced similar results. CONCLUSION: With the
inception of Medicare Part D, most MRDD beneﬁciaries with
RA and MS enrolled in Part D plans. Beneﬁciaries who had used
their MRDD beneﬁt and had worse health status—those who
appear to need prescription drug coverage most—were more
likely to enroll. Disproportionately high enrollment suggests that
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